Company intelligence / Profile preview
Lumiphore
Berkeley, California, United States
- Ownership
- Private
- Employees
- ~25
- Development stage
- Other
01
Overview
Lumiphore has developed best-in-class macrocyclic bifunctional chelators (mBFCs) for rapid, stable chelation of radioisotopes at or below physiological temperature, with high in-vivo stability. These are being applied to enable site-directed radiopharmaceuticals for both imaging and therapeutics, but there is no evidence of programs in human clinical trials as of October 2025[4][7].
- Therapeutic areas
- OncologyOther
- Modalities
- Small moleculeProteinAntibodyPeptidesAntibody fragmentRadiopharmaceutical
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Synoligo Biotechnologies
Beyond the preview
Go deeper on Lumiphore.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lumiphore.